IQVIA (IQV)
Health Care · Clinical research services and healthcare intelligence
IQVIA is a global clinical research and healthcare intelligence platform that powers drug development and commercialization with AI-driven insights from 1.2 billion de-identified patient records.
What IQVIA does
IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and pharmaceutical industries. The company operates a sophisticated, privacy-protected healthcare data platform spanning 68 petabytes of information from approximately 150,000 data suppliers, including sales, prescription, medical claims, electronic medical records, and genomics data on over 1.2 billion unique de-identified patient records. It delivers clinical and commercial capabilities—including trial design, site identification, patient recruitment, real-world evidence solutions, and AI-powered analytics—to help biotech, pharmaceutical, medical device companies, payers, and healthcare stakeholders accelerate drug development and commercialization.
Themes: ["Clinical research outsourcing","Real-world evidence / RWD","Healthcare AI / machine learning","Pharmaceutical drug development","Patient data analytics","AI-powered commercial insights","Clinical operations optimization","Life sciences intelligence"]
Fundamentals
- Price$208.97 as of 2026-07-09 close
- Market cap$34.6B as of 2026-07-10
- 1-year return+29.0% as of 2026-07-09 close
- P/E25.01 as of 2026-07-10
- Net margin+8.3% as of 2026-07-10
- Gross margin+33.0% as of 2026-07-10
- ROE+22.5% as of 2026-07-10
- Debt / equity2.55 as of 2026-07-10
- Revenue growth (YoY)+7.3% as of 2026-07-10
- Revenue CAGR (3y)+4.2% SEC XBRL
- Beta1.20 as of 2026-07-10
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Data privacy and regulatory compliance risk: operates with 1.2 billion patient records and 68 petabytes of healthcare data subject to HIPAA, GDPR, and evolving privacy regulations across 100+ countries; breach or non-compliance could trigger significant legal, financial, and reputational damage.","Customer concentration and pharmaceutical industry cyclicality: dependent on biopharmaceutical spending for outsourced R&D; economic downturns, drug development delays, or reduced biotech/pharma investment directly impact clinical research services demand and revenues.","High debt load and capital intensity: carries substantial long-term debt (13.9 billion as of Q1 2026) relative to net income margins; rising interest rates and refinancing risk could pressure profitability and financial flexibility."]
Competitors & peers
- Syneos Health
- Parexel (BeiGene subsidiary)
- Covance (part of LabCorp)
- Charles River Laboratories
- Medidata Solutions (owned by Dassault Systèmes)
- Veradigm
- Xant (commercial intelligence)
- Clinical Research Organization (CRO) and Healthcare Data & Analytics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.